RemeGen IPO: Key Drugs Show Promising Potential
RemeGen is a commercial-ready biopharmaceutical company who has filed for an IPO on the HKEX. In this insight, we explore the company's core drug...
306 Views
RemeGen IPO Initiation: Seeking a Cure
RemeGen currently has a pipeline of more than ten drug candidates. Overall, we believe that the prospectus RemeGen’s core drug assets (telitacept,...
292 Views
JW Therapeutics: Limited Upside from the Top End; Further Potential if Other Drugs Become Successful
In this insight, we take a look at the company’s drug candidates, core product relma-cel and its potential and the attractiveness of the company’s...
264 Views
ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...
326 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
326 Views